Your search for rivaroxaban returned 152 results

The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of December. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The researchers found that the risk of developing an intraocular hemorrhage was reduced with dabigatran or rivaroxaban at 365 days (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P=0.03) but not at 90 days (hazard ratio, 0.73; 95% confidence interval, 0.22 to 2.63; P=0.13).

For this group the risk of stroke was reduced by 42% (HR 0.58; 95% CI, 0.44-0.76; P<0.001), CV death by 22% (HR 0.78; 95% CI, 0.64-0.96; P=0.02) and heart attack by 14% (HR 0.86; 95% CI, 0.70-1.05; P=0.14).

The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).

Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.

While death from pulmonary embolism (PE) while watching TV may be a rare event, previous studies have demonstrated a positive association between time watching TV and the risk of death from PE (double the risk for >5hrs per day).

And antithrobotic medications linked to higher rate of hematuria-related events in older adults

The main outcomes and measures were intraocular bleeding events and associated risk ratio for NOACs, compared with warfarin.